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Abstract 
Introduction: The lymphomas [Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s 
Lymphoma (NHL)] are among the most common cancers affecting men under 45 
years.  Survival rates are now excellent, but treatment is associated with a number of 
side effects including sexual dysfunction with potential implications for compromised 
QoL (quality of life).  
Aims: To address the: (i) prevalence of sexual dysfunction among lymphoma 
survivors relative to the general population, survivors of other cancers, and in 
survivors of HL and NHL; and (ii) relationships between sexual functioning and 
disease and treatment, demographic, and psychological variables. 
  
Methods: Inclusion criteria were quantitative studies that focused on adult male 
survivors of lymphoma, included a comparison group and presented results separately 
for HL and NHL.  Standardized systematic searches were used. Information about 
design, sample size, age, time since diagnosis, type of treatment, comparison group, 
measures and findings were extracted from eligible studies. 
 
Results: Ten articles met the inclusion criteria, of which nine included patients with 
HL only, and one included patients with HL or NHL.  Sexual function was 
compromised relative to the general population, better than testicular cancer 
survivors, and worse than leukaemia survivors. Depression was consistently 
associated with sexual dysfunction. There was evidence that chemotherapy, relapse, 
reduced testosterone levels, older age at survey and worse physical QoL were 
associated with worse sexual function.  
 
Conclusions: Conclusions are limited by methodological issues including lack of 
utilization of standardized measures of sexual function and longitudinal research.  
Even so, there is evidence of sexual dysfunction among lymphoma survivors. 
Clinicians need to be sensitive to these issues. Future longitudinal work is necessary 
to determine the likelihood of recovery. 
 
Keywords: sexual function, Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, 
review; chemotherapy and sexual dysfunction 
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The lymphomas including Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s 
Lymphoma (NHL), are among the most common cancers affecting men under 45 
years of age [1]. Survival rates for both cancers have improved rapidly, and current 
five-year survival rates of 87% for HL [2] and 65% for NHL [3] have been reported. 
However a number of late effects have been identified [4] which may significantly 
compromise health-related quality of life (HRQoL). 
 
Since lymphoma does not usually affect the sexual organs, sexual dysfunction 
may not be considered by clinicians. However, sexual functioning may be affected by 
the physical impact of treatments such as chemotherapy and radiotherapy, as well as 
more psychological issues such as anxiety, depression, low self-esteem and loss of 
control over bodily functions [5]. Five or more years after diagnosis, as many as 28% 
of lymphoma survivors want information about their sexual function [6-7].  Sexual 
dysfunction has been associated with anxiety and depression in healthy individuals 
[8], and may cause distress if left untreated. Taken together these findings suggest that 
lymphoma survivors may be vulnerable to sexual dysfunction, and the associated 
psychological consequences.   
 
Sexual dysfunction might be a distressing late effect of cancer treatment.   
Both radiotherapy and chemotherapy can cause testicular damage, which may lead to 
sexual dysfunction.  Although direct radiation to the sexual organs is rare, a 
significant amount of scatter radiation may be received during pelvic irradiation, 
which can lead to erectile dysfunction through scarring of blood vessels that supply 
the penis, and subsequent inadequate blood supply [9].  Alternatively, damage to the 
pituitary gland or hypothalamus following cranial radiotherapy leads to decreased 
levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and thus 
to testosterone deficiency [10].  However, sexual dysfunction following treatment for 
lymphoma is more likely to be caused by chemotherapy [9].  Seminal research 
demonstrated that many chemotherapeutic agents progressively deplete the germinal 
epithelium lining of the seminiferous tubule, and decrease serum testosterone levels, 
leading to testicular atrophy [11-14].  Although evidence has suggested that current 
treatments are less likely to cause sexual dysfunction [15], a recent case-control study 
[16] demonstrated that male cancer survivors (41% with lymphoma), had lower 
testosterone levels than controls, and reduced sexual function. Similarly, in a study of 
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patients with lymphoma treated from 1980-2002 [10], those receiving chemotherapy 
classified as gonadotoxic were most at risk of low testosterone levels, which can lead 
to testicular atrophy.  This finding suggests that sexual dysfunction potentially 
remains a significant side effect of chemotherapy.    
 
Several studies have addressed the issue of sexual functioning in survivors of 
HL and NHL, but the evidence has not been reviewed systematically. Such a review 
would facilitate understanding of long-term sexual functioning among lymphoma 
survivors and the extent to which this may be influenced by medical, biological, 
demographic and psychosocial factors. Such information could enable healthcare 
professionals to inform patients about the likely long-term impact of their disease on 
sexual functioning and how problems may be addressed.  Given the differential 
survival rates for HL and NHL [2, 3], we decided to analyze the results both for all 
survivors of lymphoma and separately by diagnosis.   
 
We therefore report a systematic review of sexual functioning in men with HL 
or NHL. It was decided to focus on men in order to facilitate comparisons with 
testicular cancer survivors (where there have been several useful reviews on sexual 
dysfunction: [17-18]), and because there has been only limited research on sexual 
functioning in female survivors of lymphoma. The specific aims were to determine: 
(i) the prevalence of sexual dysfunction among lymphoma survivors relative to the 
general population and survivors of other cancers, and between survivors of HL and 
NHL; and (ii) the relationships between sexual functioning and disease and treatment, 
demographic, and psychological variables. 
 
Method 
The literature search aimed to identify any research study published in a peer 
reviewed journal that quantitatively assessed sexual functioning in male survivors of 
lymphoma (HL or NHL only, or if both, had conducted separate analyses for each 
group) at least six months post treatment, and included a comparison group (in order 
to provide information on risk relative to other men of a similar age; [17].   Articles 
were excluded if they: (i) included childhood cancer survivors only; (ii) were case 
reports or reviews of previous literature; or (iii) did not conduct analyses separately by 
diagnosis.   
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Three methods were used to locate relevant studies: a keyword search, a 
backward search, and a manual search of relevant journals. First, the databases 
Medline, PsycInfo and Web of Knowledge were searched for articles published in the 
English language covering the period from January 1985 (when articles were more 
likely to be identified) to June 2010 (when the search was conducted). The search 
included the following terms: Hodgkin’s disease, lymphoma (non-Hodgkin’s), libido, 
sexual function, sexual dysfunction, orgasm, erectile dysfunction, and erection. 
 
After each term had been entered into the keyword function the cancer-related 
terms were combined using the OR function, as were the sexual function terms. This 
generated 11 hits from PsycInfo, 33 hits from Medline, and 153 hits from Web of 
Knowledge. After initial review of the abstracts based on the inclusion and exclusion 
criteria, 21 articles were identified and obtained. Following the keyword search, we 
then carried out a backward search in which we located papers by examining the 
reference lists of all papers obtained from the first step. This identified five further 
articles. Following a manual search of the journals ‘Psycho-Oncology,’ ‘European 
Journal of Cancer,’ and ‘Journal of Clinical Oncology’ for the period January 1985 to 
June 2010, one further article was identified. Thus, overall 27 articles were identified, 
obtained, and assessed against the inclusion criteria. 
 
Due to heterogeneity between samples regarding size and time since treatment, 
and measurement tools (only two studies used the same measure), data pooling and 
meta-analysis was deemed inappropriate. A narrative commentary was therefore used 
to synthesize the resulting data.   
 
Results 
Following detailed review of the articles against the inclusion/exclusion criteria, 10 
articles that included eight data sets were retained.  Articles were excluded because 
they did not include a comparison group (n=10), did not report analyses separately by 
diagnosis (n=6) or did not assess survivors at least six months post treatment (n=1).  
Given the clarity of eligible papers, it was not necessary to contact researchers for 
additional information. 
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Included studies were conducted in the US (n=7), the Netherlands (n=2), and 
Norway (n=1).  Nine studies included only patients with HL, and one compared 
patients with HL and NHL.   
 
Findings were tabulated for ease of presentation.  This included information 
about aims, lymphoma sample size, age at survey, time since diagnosis, type of 
treatment, comparison group, and measures (Table 1).  
 
Aim 1: Prevalence of sexual dysfunction among lymphoma survivors relative to the 
general population and survivors of other cancers, and in survivors of HL and NHL  
 
The percentage of patients experiencing problems with sexual functioning was 
reported in seven studies.  As shown in Table 1, between 20% and 54% of patients 
experienced problems with one or more aspects of sexual function.  Sexual 
functioning was compared with general population samples in five studies.  Three 
studies found no differences between HL survivors and the general population [19-
21].  However, HL survivors scored lower than controls on the sexuality scale of the 
Maudsley Marital Questionnaire [22], and were more likely to have sex less 
frequently, were dissatisfied with the frequency of their sexual contact, and reported 
decreased sexual satisfaction and loss of interest in sex [23].   Lymphoma survivors 
(both HL and NHL) scored lower than controls on the erection, ejaculation and 
overall sexual function scales of the Brief Sexual Function Inventory [24], and had a 
higher prevalence of reduced erectile function [25].   
 
In five studies, HL survivors were compared with survivors of other cancers.  
There were no differences compared to NHL [25], or testicular cancer survivors [26].  
HL survivors experienced worse sexual functioning and lower satisfaction, and were 
more likely to report reduced sexual activity than leukaemia survivors [27].  Other 
work showed that testicular cancer survivors were more likely to report decreased 
sexual enjoyment [28], and had higher levels of ejaculatory dysfunction than HL 
survivors [29].  
 
Aim 2: The relationships between sexual functioning and disease and treatment, 
demographic, and psychological variables 
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 The relationships between sexual functioning and medical variables and 
treatment were assessed in three studies.  The chemotherapy regimens 
Mechlorethamine, vincristine, procarbazine and prednisone (MOPP), Doxorubicin, 
bleomycin, vinblastine and dacarbazine (ABVD), or Procarbazine, Alkeran, and 
vinblastine (PAVe) were associated with reduced sexual enjoyment at long-term 
follow up relative to radiation therapy only in survivors of HL [28].  However, a 
comparison between the chemotherapy regimens MOPP only, ABVD only, and 
MOPP alternating with ABVD [30] demonstrated no differences in terms of effects on 
sexual functioning for survivors of HL.  HL survivors who relapsed reported more 
sexual problems than those who remained in remission after treatment [30].  Finally, 
reduced testosterone levels were associated with worse sexual function in both HL 
and NHL survivors in one study, relative to having normal gonadal hormones [25].  A 
close correlation between gonadotoxicity of treatment and elevated LH and /or low 
testosterone levels was reported in a previous publication on the same patient sample 
[10].  Also, in the multivariate analyses reported in this manuscript [25] increasing 
age, low testosterone/elevated LH, increasing emotional distress and reduced physical 
health were all significantly associated with impaired sexual function in male 
lymphoma survivors. 
 
Relationships between sexual functioning and demographic and psychological 
variables were assessed in five studies. In two studies, (one which included HL 
survivors only [21] and one which included both HL and NHL survivors [25]), 
younger age was associated with better sexual function, particularly sexual 
satisfaction.  No other demographic correlates of sexual functioning were identified.  
Increased levels of depression were associated with psychosexual problems, 
particularly decreased sexual activity, in HL survivors only [20] and both HL and 
NHL survivors [25].  HL and NHL survivors who reported better sexual function also 
reported better physical QoL.  HL survivors who were infertile or believed they were 
infertile reported more distress than those who were fertile or believed they were 
fertile [30].    
Discussion 
Our review suggests that between 20% and 54% of patients experienced 
problems with one or more aspects of sexual function.  It was not possible to calculate 
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an exact estimate as differences between studies precluded the use of meta-analysis 
Neither were we able to determine differences between HL and NHL, since nine of 
the ten studies concentrated solely on patients with HL.  Where both cancers were 
compared, no differences in sexual function were found [25].   
 
Compared with the general population [19-21], three studies with small 
samples found no differences regarding sexual function, and the others suggest that 
sexual problems reported by lymphoma survivors, while a significant issue, may not 
always be directly related to their disease and treatment.  Despite the large sample 
(N=246) utilized by Kiserud and colleagues [25], effect sizes for impairments in 
sexual function in lymphoma survivors relative to the general population were small.  
Such impairments are therefore unlikely to be clinically significant, possibly because 
lymphoma survivors consider compromised sexual function a minor cost of survival 
[29]. Certainly, they do not differ relative to the general population on satisfaction 
with nonsexual intimacy [23].  However, of the three studies that found no 
differences, one had a small sample [19] and two used non-standardized measures 
[20-21], suggesting that further studies are required to determine whether sexual 
functioning in lymphoma survivors really is compromised relative to the general 
population.   
When compared to survivors of other cancers, lymphoma survivors had worse 
sexual function than leukaemia survivors [27], but better sexual function than 
testicular cancer survivors [28-29]. Testicular cancer survivors may experience more 
problems because their treatment (orchidectomy) visibly affects a sexual organ. 
Relative to lymphoma patients, they tend to report more dissatisfaction with 
information and support concerning sexual function [7]. 
 
 The evidence suggested that chemotherapy, relapse and reduced testosterone 
levels were associated with more sexual problems.  Previous chemotherapy may be 
associated with reduced sexual interest/ enjoyment relative to radiotherapy in 
lymphoma survivors [28]. Also, reduced testosterone levels were associated with 
reduced sexual function [25], which suggests that sexual dysfunction following 
treatment for lymphoma has an organic cause in at least some patients. Identification 
of these issues is necessary so that men can be treated appropriately i.e., with 
testosterone replacement therapy.  Recent research [10, 16] has demonstrated reduced 
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testosterone levels following chemotherapy, and greater incidence of sexual 
dysfunction in patients who have been treated by chemotherapy, suggesting this issue 
is still highly relevant.   
 
With regard to demographic and psychological variables, increasing mental 
distress was associated with reduced frequency of sexual activity [20, 25], in line with 
research on the general population [31].  Routine assessment of depression is 
warranted, in order to facilitate appropriate referrals (see also [32]). This is 
particularly important as psychological late effects of treatment are often not 
documented in medical notes and may not be addressed by clinicians [33].  Also, 
younger age was associated with better sexual function [21, 25].  This was expected, 
as the prevalence of sexual dysfunction increases with age [34] in studies from the 
general population.  Better physical QoL was also associated with better sexual 
function, possibly because more energy and fewer health problems means patients are 
able to put more effort into attaining a pleasurable sex life.   
 
Limitations are considered in relation to study design, reporting of 
demographics and results, and searches.  A number of limitations with study design 
were identified.  First, only three studies [19, 23, 25] used a standardized 
questionnaire.  Standardized instruments are required in order to determine areas in 
which deficits may be prevalent, and make direct comparisons between studies. 
Furthermore, they are widely available - 25 measures of sexual function have been 
identified [35].  Second, there were no longitudinal studies, meaning no information is 
available regarding changes during the course of treatment, or processes of recovery. 
This particularly limited our ability to  answer the question of how sexual functioning 
and medical treatment are related - as patients were assessed at different times post 
treatment it was not possible to determine the trajectory (ies) of sexual function 
following treatment.  Third, three studies [19, 26, 29] had very small samples, with 
possible insufficient power to compare groups. Fourth, only one study [25] examined 
the correlation of sexual function with testosterone levels. This is required in order to 
understand the relative contribution of biological and psychosocial factors to sexual 
problems.  Fifth, more work should address the relation between quality of life and 
sexual function.  Finally, although this review included only studies with a control 
group, good control samples from the general population regarding sexual function 
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are difficult to obtain for several reasons.  First, it is necessary to select a sample with 
the same percentage of the general population who are currently sexually active.  This 
is important as cancer survivors are less likely to be in a relationship than the general 
population (i.e., [36]).  Second, sexual function is a sensitive subject, about which 
many people refuse to complete questionnaires even when they are anonymized. 
 
Several limitations were also found with regard to reporting of demographics 
and results.  First, two studies failed to mention relationship status, which is important 
for the reason discussed above.  Second, only three of the ten studies [23, 25, 30] 
reported standard deviations. These enable comparison between studies, and are 
necessary for calculating effect sizes in meta-analysis.  
 
 There were also several limitations with regard to the searches.  The review 
was restricted by the fact that the grey literature was not searched, and only papers 
published in the English language were included.  This means there was a possibility 
of publication bias.   
 
In conclusion, we have reported a systematic review of the evidence currently 
available regarding sexual functioning in male survivors of lymphoma. We conclude 
that sexual dysfunction is an adverse late effect for a significant minority of patients, 
albeit one of low clinical significance and not necessarily a direct consequence of 
treatment.  However, given the association between low testosterone levels and 
impaired sexual function, patients should routinely be assessed and treated for low 
testosterone levels.  Furthermore, the relation between depression and impaired sexual 
function highlights the importance of assessing psychological well-being in patients.  
Further well-designed studies are required to expand the evidence base regarding 
sexual dysfunction in lymphoma survivors, in order to facilitate doctor-patient 
communication regarding likelihood of sexual dysfunction and ways in which it can 
be ameliorated. 
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Table 1: Levels of sexual function, comparison between treatments, correlates and details of measures 
Study Aims Lymphoma 
sample size 
(response 
rate) 
Age (Mean 
unless 
stated 
otherwise) 
Time since 
diagnosis 
(Mean 
unless 
stated 
otherwise) 
Type of 
treatment 
Comparison 
Group 
Measures Findings 
1. Bloom et 
al. (1993) 
[28] 
1. Compare 
physical, social and 
psychological well-
being of HL and 
testicular cancer 
survivors 
HL 85 
(88%) 
32.2 
(88.2% 
under 40) 
45.7 
months  
XRT alone: 
37.6% 
With 
MOPP: 
24.7% 
PAVe: 
24.7% 
ABVD: 
14% 
VBM: 3 
 
Testicular 
cancer 
Structured 
Interview  
1. 26%: Erectional problems 
following treatment 
2.  22.8%: decrease in quality of 
orgasm 
3. Chemotherapy: decreased 
sexual enjoyment relative to 
radiotherapy 
4. HL less likely to report 
decreased sexual enjoyment than 
testicular cancer 
 
2. Cella & 
Tross 
(1986) [19] 
1. Compare levels of 
psychological 
distress in HL 
survivors and 
healthy 
acquaintances 
HL 60 
(86.9%) 
Mean 
31.1 
Range  
6 – 140 
months  
 
Early (30):  
6 cycles 
(MOPP) + 
XRT 
Advanced: 
10-12 cycles 
(MOPP + 
ABVD) + 
XRT 
 
General 
population, 
on and off 
treatment 
Derogatis 
Sexual 
Functioning 
Inventory 
[37] 
1. Almost 1/5: difficulty in sexual 
readjustment  
 
3. Hannah 
et al. (1992) 
[26] 
1. Examine impact 
of cancer on couple 
marital and sexual 
function 
HL 24 
(married 
men + 
spouses) 
35.2 
(SD 6.8) 
34.9 
months 
 
XRT alone: 
10 
PCT: 11 
Both: 1 
Relapse: 2 
Testicular 
cancer  
Structured 
interview 
(non-
standardized) 
1. Decrease in frequency: 62.5%, 
sexual satisfaction; 37.5%; 
erectile dysfunction: 13% (0 pre-
diagnosis) 
2. No differences between 
testicular cancer and HL 
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4. Jonker-
Pool et al. 
(1998) [29] 
1. Compare sexual 
consequences of 
testicular cancer and 
HL 
HL 58 
(72.2%) 
43.3 
(SD 11.5) 
8.7 years 
(SD 6.2) 
 
XRT or PCT 
(details not 
reported) 
Testicular 
cancer 
Non-
standardized 
questionnaire 
1. Decrease in libido: 19%; 
arousal: 16%; erection: 17%; 
orgasm: 23%; sexual activity: 
24%; satisfaction:14% 
ejaculation: 9% (30% : decrease 
in 1+ sexual function), value of 
sexuality: 18%  
 
5. Kiserud 
et al. (2009) 
[25] 
1. Examine self-
reported sexual 
function and 
identify factors a/w 
reduced sexual 
function in male 
lymphoma survivors 
2. Compare sexual 
function in 
lymphoma survivors 
with normative 
group of same-aged 
controls 
HL: 138 
NHL: 108 
(84.5%) 
HL: 45.7 
(10.4) 
NHL: 49.6 
(9.6) 
HL: 15.2 
(SD 6.7) 
NHL: 14.3 
(SD 5.0) 
Chemotherapy 
Low intensity 
HL: 51%, 
NHL: 8% 
Medium; HL: 
25%, NHL: 
54% 
High; HL: 
23%, NHL: 
38% 
General 
population 
Brief Sexual 
Function 
Inventory [24] 
1. NHL lower scores than HL 
2. Low testosterone and/or 
elevated LH a/w worse sexual 
function  
3. Younger age, less emotional 
distress and better physical health 
a/w better sexual function 
4. After adjusting for relationship 
status, lymphoma survivors 
poorer erection, ejaculation, 
overall sexual satisfaction, higher 
prevalence of reduced erectile 
function and poorer sexual 
satisfaction than controls 
 
6. Kornblith 
et al. 
(1990)* 
[20]  
1. Understand 
nature and extent of 
psychosocial 
problems  
2. Identify illness, 
socio-demographic 
factors a/w 
adaptation 
HL 273 
(74%) 
(60% men) 
37 (20-66) 6.3 years 
(Range 1-
20) 
 
PCT: 80% 
XRT + 
PCT: 16% 
XRT 
alone: 4% 
General 
population 
8 items, plus 
Global Sexual 
Satisfaction 
Index (from 
Derogatis 
Sexual 
Function 
Inventory) 
1. Sexual satisfaction similar to 
controls 
2. 37% : 1 + sexual problems 
(decreased satisfaction: 31%; 
interest: 21%; activity:18%; 
erectional problems: 13%; ) 
3. Psychosexual problems 
attributed to cancer a/w increased 
distress (BSI; IES intrusion, 
avoidance; POMS; PAIS-R) 
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7. Kornblith 
et al. 
(1992)*[30] 
1. Compare MOPP, 
ABVD, and 
MOPP/ABVD 
chemotherapy in 
terms of physical, 
psychosocial and 
psychosexual effects 
on HL survivors 
Subset of 6 
93 (76%) 
(60% men) 
Median 
35 (20-
59) 
2.2 years 
(Range  
1-5) 
 
MOPP: 31 
ABVD: 33 
MOPP/ABVD: 
29 
Treatment 
types  
As for [20] 1. If  believed infertile – more 
distress (PAIS; POMS) 
2.Relapse a/w more sexual 
problems attributed to cancer 
 
8. Kornblith 
et al. 
(1998)* 
[27] 
1. Compare long-
term adaptation of 
HL and leukaemia 
survivors 
As 6 37 (20-
66) 
5.9 
(Range  
1-20) 
As 6 Leukaemia As for [20] 1. HL worse sexual function than 
leukaemia, lower satisfaction  
2. HL survivors more likely to 
report reduced sexual activity as 
result of cancer  
 
9. Recklitis 
et al. (in 
press) [21] 
1. Determine nature 
and extent of sexual 
dysfunction after 
HL 
465 (49.7% 
men) 
(60.6%) 
Median 
44 (20-
70+) 
18.32  
(SD 7.31) 
XRT: 93% 
PCT: 37% 
General 
population 
(patients’ 
siblings) 
As for [20] 1. 54.2%: decreased sexual 
activity; 41.4% decreased interest 
2. No differences relative to 
controls 
3. Satisfaction lower in older 
survivors 
 
10. Van 
Tulder et al. 
(1994) [23] 
1. Determine QoL 
of long-term HL 
survivors 
HL: 81 
(92%) 
(51.8% 
men) 
 
Men: 
(44.3, 
SD 
11.1) 
14 years 
(SD 2) 
 
XRT: all 
+ vinblastin: 5 
+ MOPP: 14 
General 
population 
Maudsley 
Marital 
Questionnaire 
(sexuality 
scale) [22] 
1. Patients lower scores on 
sexuality scale than controls 
2. ¼ - no interest in sex (controls: 
10%)  
3. ½ - sex at least once a week 
(controls: 73%) 
4. 29% dissatisfied with 
frequency of sexual contact 
(controls: 16%) 
5. 12% dissatisfied with quality 
of sexual contact (controls: 5%) 
* These studies were drawn from the same population 
** Gender was controlled for in all analyses 
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Glossary: XRT – radiotherapy; MOPP – Mechlorethamine, vincristine, procarbazine, prednisone; PAVe - procarbazine, Alkeran, 
vinblastine; ABVD – Doxorubicin, bleomycin, vinblastine, dacarbazine; VBM – vincristine, bleomycin, methotrexate; PCT – 
polychemotherapy; a/w – associated with 
